

BMJ Paediatrics Open

BMJ Paediatrics Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Paediatrics Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjpaedsopen.bmj.com>).

If you have any questions on BMJ Paediatrics Open's open peer review process please email info.bmjpo@bmj.com

BMJ Paediatrics Open

Pharmacokinetics of a microdosed cocktail of 3 direct oral anticoagulants in children with congenital heart defects: study protocol for a single centre clinical trial (DOAC-Child)

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2022-001662
Article Type:	Protocol
Date Submitted by the Author:	01-Sep-2022
Complete List of Authors:	Hermann, Simon; UniversitätsKlinikum Heidelberg, Department of Clinical Pharmacology and Pharmacoepidemiology Mikus, Gerd; UniversitätsKlinikum Heidelberg, Department of Clinical Pharmacology and Pharmacoepidemiology Chobanyan-Jürgens, Kristine; UniversitätsKlinikum Heidelberg, Department of Clinical Pharmacology and Pharmacoepidemiology; UniversitätsKlinikum Heidelberg, Pediatric Clinical-Pharmacological Trial Centre Gorenflo, Matthias; UniversitätsKlinikum Heidelberg, Department of Paediatric and Congenital Cardiology Ziesenitz, Victoria; UniversitätsKlinikum Heidelberg, Department of Paediatric and Congenital Cardiology
Keywords:	Cardiology, Pharmacology

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Pharmacokinetics of a microdosed cocktail of 3 direct oral anticoagulants in children with**
4 **congenital heart defects: study protocol for a single centre clinical trial (DOAC-Child)**
5
6
7

8 **Simon A. Hermann¹, Gerd Mikus¹, Kristine Chobanyan-Jürgens^{1,3}, Matthias Gorenflo²,**
9 **Victoria C. Ziesenitz²**
10

11 ¹ Department of Clinical Pharmacology and Pharmacoepidemiology
12

13 Heidelberg University Hospital
14

15 Im Neuenheimer Feld 410
16

17 69120 Heidelberg, Germany
18

19 ² Centre for Child and Adolescent Medicine – Department of Paediatric and Congenital
20 Cardiology
21

22 Heidelberg University Hospital
23

24 Im Neuenheimer Feld 430
25

26 69120 Heidelberg, Germany
27

28 ³ Pediatric Clinical-Pharmacological Trial Centre (paedKliPS) - Centre for Pediatric and
29 Adolescent Medicine
30

31 Heidelberg University Hospital
32

33 Im Neuenheimer Feld 430
34

35 69120 Heidelberg, Germany
36
37
38
39
40
41
42

43 **Corresponding author:**

44 Victoria C. Ziesenitz
45

46 Centre for Child and Adolescent Medicine – Department of Paediatric and Congenital
47 Cardiology
48

49 Heidelberg University Hospital
50

51 Im Neuenheimer Feld 430
52

53 69120 Heidelberg, Germany
54

55 Email: ziesenitz.md@gmail.com
56

57 Telephone: +49 6221/56 4605
58
59
60

ORCID:

SAH: <https://orcid.org/0000-0002-5561-8022>

GM: <https://orcid.org/0000-0003-1783-133X>

KCJ: <https://orcid.org/0000-0002-9118-9464>

MG: <https://orcid.org/0000-0002-3326-5959>

VCZ: <https://orcid.org/0000-0003-2836-4212>

Authors' contributions:

SAH: writing of trial protocol and manuscript, sub-investigator, conduct of the trial.

GM: conception of the trial, writing of trial protocol, biostatistician.

KCJ: conception of the trial, writing of trial protocol, deputy investigator

MG: conception of the trial, writing of trial protocol, principal investigator, conduct of the trial

VCZ: conception of the trial, writing of trial protocol, deputy investigator, conduct of the trial

Word count:

Manuscript: 2452 words (2500)

Abstract: 283 words (300)

Trial registration numbers:

EudraCT 2019-001759-38

DRKS00021455

Declaration of interests:

This is an investigator initiated clinical trial sponsored by the Heidelberg University Hospital, there are no financial interests of any person involved.

Funding:

There was no external funding received for the conduct of this study.

Abstract

Introduction: Direct oral anticoagulants (DOACs) are direct inhibitors of coagulation factor Xa and are frequently used in adults for different indications such as deep vein thrombosis or non-valvular atrial fibrillation. Paediatric patients might benefit as well from DOACs because the simplicity and convenience of their use is likely to decrease physical and psychological stress related to invasive procedures associated with phenprocoumon and heparin therapy. Thus it is expected that the future use of DOACs will ultimately improve compliance and overall safety of anticoagulant therapies in paediatric populations. To assure safe and effective use the clinical pharmacology and pharmacokinetics (PK) of these drugs need to be evaluated in children.

Methods and analysis: This study is a single centre, open-label, clinical trial in a paediatric population with non-cyanotic congenital heart defects. After having obtained informed consent from the parents, each participant will receive a single oral administration of a drinkable solution of a microdose cocktail of 3 FXa inhibitors consisting of apixaban (12.5 µg), rivaroxaban (12.5 µg), edoxaban (50 µg), plus a microdose of the two probe drugs midazolam (10 µg) and yohimbine (25 µg). Serial blood samples will be collected at specified time points before and up to 25 h after cocktail administration. The primary PK endpoint will be the area under the plasma concentration time curve ($AUC_{0-\infty}$) of apixaban, rivaroxaban and edoxaban. Secondary PK outcomes will be C_{max} , t_{max} , $t_{1/2}$, Cl/F , and V_{ss}/F . Safety and tolerability of the microdose cocktail will be evaluated as well by collection of adverse events.

Ethics: This study has been approved by the responsible Ethics Committee of the Medical Faculty of Heidelberg University.

Dissemination: Study results will be presented at international scientific meetings and published in peer-reviewed journals.

What is known about the subject?

- Current anticoagulation regimes in children with congenital heart defects consist of phenprocoumon, (low molecular weight) heparin, or antiplatelet agents. Disadvantages of these regimes comprise invasive monitoring (phenprocoumon) or invasive administration techniques (heparin).
- Direct oral anticoagulants (DOAC) are a relatively new class of anticoagulants which have been approved and are widely used in adults.
- There are no data available regarding the pharmacokinetics of DOACs in pediatric heart patients.
- The expression of drug metabolising enzymes involved in the eliminations of DOACs varies during human development and growth.

What this study hopes to add:

- Evaluation of the pharmacokinetics of three DOACs: rivaroxaban, edoxaban, apixaban simultaneously in children with congenital heart disease aged 6 months to 6 years using a microdose-cocktail approach.
- Evaluation of CYP3A and CYP2D6 metaboliser status using the microdosed probe drugs midazolam and yohimbine in pediatric heart patients.

How this study might affect research, practice and/ or policy.

- The pharmacokinetics of rivaroxaban, edoxaban and apixaban will be evaluated regarding their interindividual variability and their potential for drug-drug interactions.
- The DOAC with the most favorable profile will be selected and a subsequent study using therapeutic doses will be conducted.
- The overall goal of this study is to pave the way for less painful pediatric anticoagulation.

Introduction

Congenital heart disease (CHD) is the most common form of major congenital anomalies. Congenital heart defects are defined as a structural abnormality of the heart and/or great vessels that is present at birth. Reported birth prevalence of CHD varies between 8-12 per 1000 live births^{1 2}. The prevalence of complex CHD diagnosis is reported to be 0.8 to 2.2 per 1000 live births depending on the demographics of the study population, the inclusion criteria, and the study era. Severe CHD accounts for most of the morbidity and mortality attributable to CHD³. A recent German analysis which focused on patients with CHD born between 1996 and 2015 showed that the number of patients with severe CHD had increased significantly since 2008/2009. About 9.4% of patients in this cohort had complex CHD classified as univentricular heart⁴. Certain patients with severe congenital heart disease require temporary or lifelong anticoagulation. This applies especially to patients after biological (temporary anticoagulation) or mechanical (lifelong anticoagulation) heart valve replacement, or patients after Glenn or Fontan palliation, when the blood flows passively through the pulmonary circulation at low velocity.

The currently used anticoagulants in children are either oral phenprocoumon or warfarin, heparin continuous infusion, and subcutaneously injected low molecular weight heparins, the latter often limited to short-term therapy.

Since 2008, direct oral anticoagulants (DOAC) including the drugs dabigatran, rivaroxaban, apixaban and edoxaban have been approved for adults in Europe and the US, and efficacy, safety and pharmacokinetic data have been obtained in adults. These drugs so far have not yet been adequately studied in children and are currently not approved for the use in paediatric heart patients. For children and adolescents, there are ongoing studies on rivaroxaban and apixaban, but most of them are not yet completed or published⁵.

There are body-weight adjusted treatment recommendations available for rivaroxaban in children with venous thromboembolism. Children with a body weight 10 kg or more should be

1
2
3 treated with a daily dose of 9 mg or higher, depending on the actual body weight⁶. Assessment
4 of 92 children aged < 6 month – 17 years with weight-adjusted rivaroxaban after previous
5 therapeutic treatment with common medication such as low-molecular weight heparin because
6 of venous thromboembolism was performed. No major bleeding was observed during the
7 clinical trial in 92 children aged < 6 months to 17 years.
8
9

10
11
12 An oral microdose DOAC cocktail (μ -FXaI) containing apixaban (25 μ g), edoxaban (50 μ g)
13 and rivaroxaban (25 μ g) has been successfully used in adults to study drug-drug interactions^{7,8}.
14
15 The pharmacokinetics (PK) of these 3 FXaI, obtained after simultaneous administration,
16 correspond well with the PK characteristics after therapeutic FXaI doses (dose-proportional
17 pharmacokinetics). In one study in 18 healthy adults (> 18 years) the effect of ketoconazole on
18 μ -FXaI revealed the quantitative drug-interaction effects ketoconazole on the three FXaI was
19 reproducible with the clearances of μ -FXaI comparable to already published data of therapeutic
20 doses⁷.
21
22

23
24 In children with certain heart defects long-term anticoagulation is required, which is usually
25 achieved by vitamin K-antagonists. Only few studies focusing on direct oral anticoagulants
26 (DOAC) in children have been carried out so far, or are still ongoing^{5,9}. Currently, there are
27 only limited data published for edoxaban or apixaban in children¹⁰. The few results from studies
28 of rivaroxaban PK report a favorable safety profile and pharmacokinetics comparable to those
29 already known for adults⁹. Therefore, it is important to generate pharmacokinetic data of DOAC
30 in children of this young age with congenital heart disease without an increased risk of bleeding,
31 which would be harmful to this vulnerable group, simultaneously for all three DOAC.
32
33 Therefore, this study will use the simultaneous administration of microdosed drugs only to
34 assess the pharmacokinetics, safety, and tolerability.
35
36

37
38 In order to obtain data of CYP3A and CYP2D6 activity in young children, microdose co-
39 administration of the CYP3A substrate midazolam (MDZ; 10 μ g) and the CYPD6 substrate
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 yohimbine (YOH; 25 µg) as probe drugs along with the three FXaI products will be carried out.

4
5 Thus, the microdose cocktail to be used in the study contains a total of 5 different drugs which
6
7
8 will be administered simultaneously by oral route.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Confidential: For Review Only

Methods and analysis

Study Design

This is an open-label, single-centre, single dose clinical trial in a paediatric population with non-cyanotic congenital heart defects at the Department of Paediatric and Congenital Cardiology of the Heidelberg University Hospital in cooperation with the paediatric Clinical Pharmacological Study Centre (paedKliPS). This protocol was designed following the SPIRIT guidelines¹¹.

Study population

Infants and children aged 6 months up to 6 years with a body weight >7 kg who are admitted to the paediatric cardiology wards for the surgical correction on a non-cyanotic congenital heart defect are included. Children who are treated with anticoagulants, who have a coagulopathy or lesions or conditions which are associated with a significant risk for major bleeding are excluded, as well as children who have kidney or liver insufficiency, or are treated with drugs known to be relevant inducers or inhibitors of drug metabolizing enzymes. Detailed inclusion and exclusion criteria are listed in Supplemental Table 1.

For the purpose of surgery all patients are under routine continuous cardiorespiratory monitoring (Intellivue, Philips Healthcare, Eindhoven, The Netherlands), have central vascular access, and a feeding tube, depending on the respective age and the clinical condition.

Primary objective

Assessment of the pharmacokinetics of rivaroxaban, apixaban and edoxaban, when co-administered as a microdose cocktail (apixaban 12.5 µg, rivaroxaban 12.5 µg, edoxaban 50 µg) in children with congenital heart defects, aged 0.5-6 years.

Secondary objectives

- To compare the pharmacokinetics of the FXaI in children with those reported in healthy adults and patients from literature.
- To characterise the CYP3A activity by means of a midazolam microdose in children.
- To characterise the CYP2D6 activity by means of a yohimbine microdose in children.
- To evaluate tolerability and safety of this microdose cocktail in children.

Study Outcome

Primary outcome is the area under the concentration-time curve ($AUC_{0-\infty}$) of the three DOACs apixaban, edoxaban, and rivaroxaban. Secondary outcomes include standard PK parameters (C_{max} , t_{max} , $t_{1/2}$, Cl/F , and V_{ss}/F) of each FXaI and yohimbine, as well as the metabolic clearance of midazolam by means of AUC_{2-4h}^{12} .

Recruitment

Recruitment takes place at the Department of Paediatric and Congenital Cardiology. Prior to the surgical intervention parents of potential participants are addressed regarding the study which serves as short information about the clinical trial. After the surgery detailed information is given and discussed with both parents. After full explanation of the purpose, the procedures involved, the expected duration, the potential risks and benefits and any discomfort of the clinical trial both parents sign the informed consent form before any study procedures are carried out.

Screening

The screening visit is defined as accurate check of all diagnostic findings which were made in course of the pre-operative assessment to evaluate eligibility. This is done after the surgery by a trial team physician in order to check inclusion and exclusion criteria.

Interventions

1
2
3 The intervention may begin on postoperative day 3 (about 72 hours after surgery) with the oral
4 administration of the study drugs. They are dissolved in 110 ml tap water to ensure comfortable
5 oral application. If the patient has a feeding tube, this will be used for administration. All
6 patients have as a clinical routine measure prior to cardiac surgery a central venous line. Vital
7 parameters and other clinical or laboratory which are necessary to ensure patients safety are
8 extracted from the daily documentation during clinical routine.
9

17 ***Sample collection***

20 PK blood samplings will be collected via a central venous line and time points are dependent
21 on bodyweight (Figure 1). The total amount of blood drawn will be 25 mL over 25 hours for
22 children of at least 10 kg. This includes 17 samples to evaluate PK parameters (S-Monovette®
23 1.2 mL lithium heparin collection tubes, Sarstedt, Nümbrecht, Germany) and 3 safety checks
24 in which the coagulation parameters will be observed (S-Monovette® 1.4 mL citrate collection
25 tubes, Sarstedt, Nümbrecht, Germany). This is equivalent to a loss of blood volume of 3.28 %
26 of a child weighing 10 kg. For children weighing 7 to 9.9 kg a reduced sampling scheme (12
27 PK samples and 3 coagulation samples) will be applied to limit the blood loss (18.6 mL in 24
28 hours equivalent to 3.54 % for a child weighing 7 kg)¹³. All PK samples will be analysed in the
29 Clinical Analytical Laboratory of the Department of Clinical Pharmacology and
30 Pharmacoepidemiology at the University Hospital Heidelberg¹⁴.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 Midazolam will be measured in 5 samples (before and 2, 2.5, 3, and 4 h after administration)
48 using an established limited sampling strategy¹² and yohimbine¹⁵ in the samples taken up to 12
49 hours after administration.
50
51
52
53

54 Three coagulation checks (quick, INR, aPTT) are obtained before, 2 and 24 or 25 h after drug
55 administration.
56
57
58
59

60 ***End of trial (EOT)***

1
2
3 After the last blood sample the EOT visit includes reviewing the last clinical examination and
4
5 laboratory assessment, which both are performed at least once during 24 hours by clinical
6
7 routine.
8
9

10 ***Concomitant medication***

11
12
13
14 Any necessary medication (judged by a responsible physician) for the best clinical care and/or
15
16 emergency treatment is permitted. Concomitant medication will be documented (date, time,
17
18 dose, route of administration) by a member of the trial team. For safety reasons simultaneous
19
20 administration of anticoagulants, thrombolytics, platelet inhibitors such as GPIIb/IIIa-inhibitors
21
22 and P2Y₁₂ inhibitors, and thienopyridine (clopidogrel) are prohibited for the duration of the
23
24 trial.
25
26
27

28 **Sample size calculation**

29
30 Since no PK data in young children are available for the microdosed FXaI cocktail, no formal
31
32 sample size calculation could be performed. It is planned to enroll up to 20 children with
33
34 congenital heart defects. This number of patients is consistent with sample sizes of similar
35
36 exploratory PK studies, which is expected to provide sufficient information on PK, safety, and
37
38 tolerability of the μ -FXaI cocktail and the suitability of this methodology in future clinical
39
40 paediatric drug development. In addition, it is expected that robust single-dose PK data of 3
41
42 FXaI in a young paediatric population will be generated to provide first guidance for dose
43
44 adjustment in clinical use. An outstanding feature of our methodology is the simultaneous
45
46 administration of 3 substances, so that each substance does not have to be examined in separate
47
48 studies.
49
50
51
52
53

54 **Data management**

55
56
57 Clinical routine data are also documented for this clinical trial. Vital signs (i.e. blood pressure,
58
59 heart rate) are documented at screening, prior to the drug administration, at any specific PK
60

1
2
3 timepoint, and at EOT. Concomitant medication and adverse events are also recorded. Printed
4
5 source data sheets are used for the primary data collection and documentation. All source data
6
7 information are timely transferred to the clinical trial management database (Promasys,
8
9
10 OmniComm Systems, Fort Lauderdale, USA).

11 12 13 **Data analysis and missing data**

14
15
16 Standard PK parameters (C_{\max} , t_{\max} , $AUC_{0-\infty}$, $t_{1/2}$, Cl/F , and V_{ss}/F) of each FXaI and yohimbine
17
18 will be calculated by non-compartmental analyses (Monolix 2021R2, Lixoft SAS, Antony,
19
20 France) and its results will be presented by descriptive statistics (GraphPad Prism 8.0.0 for
21
22 Windows, GraphPad Software, San Diego, California USA). CYP3A activity will be quantified
23
24 using the estimated metabolic clearance of midazolam by means of AUC_{2-4h}^{12} .
25
26
27

28 Individual missing or inconsistent data will be subject to a simple edit query process. Eventually
29
30 missing data will not be imputed.
31
32

33 34 **Patient and Public Involvement**

35
36
37 Patients and/ or the public were not involved in any stages of this clinical trial: study design/
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Ethics and dissemination

Ethics approval

The study protocol (Version 4.0), patient information and informed consent form were approved by the ethics committee of the Medical Faculty of Heidelberg University (AFmo-606/2019) and the German competent authority (BfArM).

To enable the participation for children younger than 2 years and with a weight lower than 10 kg a protocol amendment was submitted and approved (Protocol Version 5.1). For these patients, a reduced sampling scheme was introduced to keep the relative loss of blood volume below 5 % in 24 hours¹³.

Study monitoring

A trained clinical trial monitor is assigned from the Department of Clinical Pharmacology and Pharmacoepidemiology at the University Hospital Heidelberg to perform the monitoring of this clinical trial.

Safety considerations

All medications will be administered as a subtherapeutic microdose. Although it is unlikely that the achieved concentrations of the administered trial medications confer any pharmacological effect or adverse drug reaction, a maximum degree of safety is essential in this vulnerable population.

Benefit and Risk assessment

There is no direct benefit to the patients or their parents. Because of the clinical setting in which the study will be carried out, no additional invasive procedures have to be performed. All participants are admitted as inpatient to the paediatric cardiac wards, where continuous cardiorespiratory monitoring and central vascular access, etc. are already provided.

1
2
3 In order to reduce additional burden of study procedures to the patient in the postoperative
4 phase, after having signed informed consent, the patients' medical history, findings during the
5 clinical examination and other parameters routinely assessed and documented during the
6 treatment for these patients will also be completely recorded for this clinical trial. This is a
7 common approach in clinical studies. Due to the sensitive drug assay, the amount of blood taken
8 for the PK analyses is minimised.
9

10
11 All study drugs will be given as single microdoses only which does not elicit any
12 pharmacological effects or adverse events⁷. The combination of microdoses of apixaban,
13 rivaroxaban, edoxaban has been used in adults and at FXaI peak concentrations, International
14 normalised ratio (INR) increased just by 3.9% and activated partial thromboplastin time (aPTT)
15 by 3.1% which was clinically not relevant⁷. No bleeding complications occurred. Clinically
16 relevant non-major bleeding (menorrhagia and gingival bleeding) has been observed in four
17 children with venous thromboembolism taking therapeutic rivaroxaban within the Einstein-Jr
18 phase III study¹⁶.
19

20
21 Due to very sensitive analytical assay for apixaban and rivaroxaban, the dose of apixaban and
22 rivaroxaban is halved to 12.5 µg each compared to the adult study. MDZ and yohimbine were
23 used frequently in adults and no relevant AEs were observed at all.
24

25
26 Thus, there is no risk of drug accumulation and the risk for adverse events (AE) or toxicity is
27 minimal. We do not expect any bleeding complications by µ-FXaI. If a case of bleeding
28 complications the effects of rivaroxaban and apixaban can be reversed by Andexanet alpha. It
29 also inhibits the function of all heparins¹⁷. We have summarised the case reports where children
30 were exposed to rivaroxaban¹⁸⁻²¹ or edoxaban²², intentionally or unintentionally in the
31 supplemental material (Supplemental Table 2).
32

33
34 In summary, potential risks of participation in this clinical trial are small and predictable. The
35 trial drugs are administered at sub-therapeutic microdoses on one occasion, so that no adverse
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 drug reactions are to be expected. The participant's suitability will be carefully evaluated, and
4
5 their health will be closely monitored during the trial.
6
7

8 **Publications and Data access**

9

10
11 The results of this investigation will be published in an international scientific peer-reviewed
12
13 journal. It is not planned to make the data publicly available.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure 1:** Study design assessing the pharmacokinetics of rivaroxaban, apixaban, edoxaban as
4 well as the CYP3A and CYP2D6 enzyme activity in children with congenital heart defects.
5
6
7
8 Upper timeline: Sampling schedule for children weighing 10 kg and more, lower timeline:
9
10 sampling schedule for children weighing 7-9.9 kg.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Confidential: For Review Only

References


1. Liu Y, Chen S, Zuhlke L, et al. Global birth prevalence of congenital heart defects 1970-2017: updated systematic review and meta-analysis of 260 studies. *Int J Epidemiol* 2019 doi: 10.1093/ije/dyz009
2. van der Linde D, Konings EE, Slager MA, et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. *Journal of the American College of Cardiology* 2011;58(21):2241-7. doi: 10.1016/j.jacc.2011.08.025 [published Online First: 2011/11/15]
3. Egbe A, Uppu S, Lee S, et al. Changing prevalence of severe congenital heart disease: a population-based study. *Pediatric cardiology* 2014;35(7):1232-8. doi: 10.1007/s00246-014-0921-7 [published Online First: 2014/05/16]
4. Pfitzer C, Helm PC, Ferentzi H, et al. Changing prevalence of severe congenital heart disease: Results from the National Register for Congenital Heart Defects in Germany. *Congenital heart disease* 2017;12(6):787-93. doi: 10.1111/chd.12515 [published Online First: 2017/07/19]
5. von Vajna E, Alam R, So TY. Current Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric Population. *Cardiol Ther* 2016;5(1):19-41. doi: 10.1007/s40119-015-0054-y [published Online First: 2016/01/08]
6. Lensing AWA, Male C, Young G, et al. Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study. *Thromb J* 2018;16:34. doi: 10.1186/s12959-018-0188-y [published Online First: 2019/01/02]
7. Mikus G, Foerster KI, Schaumaeker M, et al. Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs. *Clinical pharmacokinetics* 2019 doi: 10.1007/s40262-019-00749-1

- 1
2
3 8. Rohr BS, Foerster KI, Blank A, et al. Perpetrator Characteristics of Azole Antifungal Drugs
4
5 on Three Oral Factor Xa Inhibitors Administered as a Microdosed Cocktail. *Clinical*
6
7 *pharmacokinetics* 2022;61(1):97-109. doi: 10.1007/s40262-021-01051-9 [published
8
9 Online First: 2021/07/18]
- 10
11
12 9. Male C, Thom K, O'Brien SH. Direct oral anticoagulants: What will be their role in
13
14 children? *Thromb Res* 2019;173:178-85. doi: 10.1016/j.thromres.2018.06.021
15
16 [published Online First: 2018/07/19]
- 17
18
19 10. Esch JJ, Hellinger A, Friedman KG, et al. Apixaban for treatment of intracardiac
20
21 thrombosis in children with congenital heart disease. *Interactive cardiovascular and*
22
23 *thoracic surgery* 2020;30(6):950-51. doi: 10.1093/icvts/ivaa041 [published Online
24
25 First: 2020/03/30]
- 26
27
28 11. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard
29
30 protocol items for clinical trials. *Ann Intern Med* 2013;158(3):200-7. doi:
31
32 10.7326/0003-4819-158-3-201302050-00583 [published Online First: 2013/01/09]
- 33
34
35 12. Katzenmaier S, Markert C, Riedel KD, et al. Determining the time course of CYP3A
36
37 inhibition by potent reversible and irreversible CYP3A inhibitors using A limited
38
39 sampling strategy. *Clinical pharmacology and therapeutics* 2011;90(5):666-73. doi:
40
41 10.1038/clpt.2011.164 [published Online First: 2011/09/23]
- 42
43
44 13. Howie SR. Blood sample volumes in child health research: review of safe limits. *Bull*
45
46 *World Health Organ* 2011;89(1):46-53. doi: 10.2471/BLT.10.080010 [published
47
48 Online First: 2011/02/25]
- 49
50
51 14. Mikus G, Foerster KI, Schaumaeker M, et al. Microdosed Cocktail of Three Oral Factor
52
53 Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.
54
55 *Clinical pharmacokinetics* 2019;58(9):1155-63. doi: 10.1007/s40262-019-00749-1
56
57 [published Online First: 2019/03/05]
- 58
59
60

- 1
2
3 15. Vay M, Sauter M, Mikus G, et al. Quantification of microdosed oral yohimbine and its
4
5 major metabolite in human plasma in the picogram range. *Bioanalysis*
6
7 2019;11(16):1459-67. doi: 10.4155/bio-2019-0129 [published Online First:
8
9 2019/08/15]
10
11
12 16. Monagle P, Lensing AWA, Thelen K, et al. Bodyweight-adjusted rivaroxaban for children
13
14 with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-
15
16 arm, phase 2 studies. *Lancet Haematol* 2019;6(10):e500-e09. doi: 10.1016/S2352-
17
18 3026(19)30161-9 [published Online First: 2019/08/20]
19
20
21 17. Baumann Kreuziger L, Karkouti K, Tweddell J, et al. Antithrombotic therapy
22
23 management of adult and pediatric cardiac surgery patients. *Journal of thrombosis and*
24
25 *haemostasis : JTH* 2018;16(11):2133-46. doi: 10.1111/jth.14276
26
27
28 18. Van Bruwaene L, Huisman A, Urbanus RT, et al. Heparin-resistant Thrombosis Due to
29
30 Homozygous Antithrombin Deficiency Treated With Rivaroxaban: A Case Report. *J*
31
32 *Pediatr Hematol Oncol* 2016;38(8):658-60. doi: 10.1097/MPH.0000000000000608
33
34
35 19. Carr BM, Roy DJ, Bangh SA, et al. Anti-factor Xa Monitoring and Activated Charcoal for
36
37 a Pediatric Patient With Rivaroxaban Overdose. *Clin Pract Cases Emerg Med*
38
39 2018;2(3):247-50. doi: 10.5811/cpcem.2018.5.38373
40
41
42 20. Martinelli I, Bucciarelli P, Artoni A, et al. Anticoagulant treatment with rivaroxaban in
43
44 severe protein S deficiency. *Pediatrics* 2013;132(5):e1435-9. doi: 10.1542/peds.2013-
45
46 1156
47
48
49 21. Ma JY, Zhang X, Li XF, et al. Thrombotic storm in a 4-year-old boy with a thrombus in
50
51 the right atrium. *Int J Immunopathol Pharmacol* 2018;32:2058738418778121. doi:
52
53 10.1177/2058738418778121
54
55
56 22. Watanabe K, Arakawa Y, Yanagi M, et al. Management of severe congenital protein C
57
58 deficiency with a direct oral anticoagulant, edoxaban: A case report. *Pediatric blood*
59
60 *& cancer* 2019;66(6):e27686. doi: 10.1002/pbc.27686

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Confidential: For Review Only



Study design assessing the pharmacokinetics of rivaroxaban, apixaban, edoxaban as well as the CYP3A and CYP2D6 enzyme activity in children with congenital heart defects. Upper timeline: Sampling schedule for children weighing 10 kg and more, lower timeline: sampling schedule for children weighing 7-9.9 kg.

254x190mm (96 x 96 DPI)

Hermann S et al.: Pharmacokinetics of a microdosed cocktail of 3 direct oral anticoagulants in children with congenital heart defects: study protocol for a single centre clinical trial, BMJ Pediatrics Open 2022.

Supplemental Table 1:

Detailed inclusion and exclusion criteria of DOAC-Child

<i>Inclusion criteria</i>	<i>Exclusion criteria</i>
<ul style="list-style-type: none"> • Infants and children aged 6 month up to 6 years (inclusive) • Body weight ≥ 7 kg • Admitted as inpatient to the paediatric cardiac wards after congenital cardiac surgery, • Cardiac defects: non-cyanotic congenital heart defects such as e.g. atrial septal defect, ventricular septal defect • Availability of a central vascular access • Otherwise healthy children as determined by medical assessment consisting of a medical history, physical examination, an ECG, and a laboratory evaluation, all performed within the clinical routine, that all must show no clinically relevant abnormalities • Minor deviations of laboratory values from the normal range may be acceptable in the pre-operative assessment, if judged by the 	<ul style="list-style-type: none"> • Intake of a substance known to induce or inhibit drug metabolizing enzymes or drug transporters within a period of less than 10 times the respective elimination half-life or two weeks, whatever is longer • Simultaneous treatment with anticoagulants (i.e. phenprocoumon, warfarin, heparin - prior intake of heparin is allowed if more than 24 h prior to the start of study) • Active, clinical relevant bleeding • Any hepatic disease which could lead to coagulopathy or clinical relevant risk of bleeding • Lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous

Hermann S et al.: Pharmacokinetics of a microdosed cocktail of 3 direct oral anticoagulants in children with congenital heart defects: study protocol for a single centre clinical trial, BMJ Pediatrics Open 2022.

<p>investigator to be of no clinical relevance for this trial.</p> <p>Criteria include, but are not limited to</p> <ul style="list-style-type: none"> • ALT \leq ULN x 1.1 • AST \leq ULN x 1.2 • Bilirubin \leq ULN x 1.2 (this does not apply to patients with Gilbert's syndrome) • Creatinine \leq ULN + 0.1 mg/dl • Haemoglobin > 10 g/dl (pre- and postoperatively) <ul style="list-style-type: none"> • Both parents (or legal representatives) have to be able to communicate well with the investigator, to understand and comply with the requirements of the trial • Voluntarily signed informed consent after full explanation of the objectives, meaning and consequences of the trial to both parents (or legal representatives) of the participant. The informed consent will be obtained after the surgery but before any specific study procedures will be carried out 	<p>malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities</p> <ul style="list-style-type: none"> • Uncontrolled severe hypertension/hypotension • Severe respiratory insufficiency • Tachycardic arrhythmias • Renal/Liver insufficiency • Glaucoma • Gastrointestinal ulceration • Clinical relevant mental disorder • Any physical disorder that could interfere with the participant's safety during the clinical trial or with the trial objectives • Body weight lower than 7 kg • Allergies (except for mild forms of hay fever) or history of hypersensitivity reactions/ intolerance to the study drugs • Any acute or chronic illness or clinically relevant finding during the clinical course known or expected to modify absorption, distribution, metabolism, or excretion of the drug under investigation • Any participation in an interventional clinical trial within 30 days before inclusion.
---	--

Hermann S et al.: Pharmacokinetics of a microdosed cocktail of 3 direct oral anticoagulants in children with congenital heart defects: study protocol for a single centre clinical trial, BMJ Pediatrics Open 2022.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	<ul style="list-style-type: none">• Specific exclusion criteria for Midazolam: Administration of midazolam less than 48 h prior to the start of study
--	---

Confidential: For Review Only

Supplemental Table 2: Case reports about children who were exposed to direct oral anticoagulants

DOAC	Patient	Indication	Dose	Result
Rivaroxaban ¹	12 year old girl	DVT	20 mg once daily for 5 days	Rivaroxaban trough level after 2 days 109 ng/mL and after 5 days 100 ng/mL. No bleeding.
Rivaroxaban ²	35 month old boy	Accidental intake	200 mg (16 mg/kg)	Activated charcoal (2 g/kg) p.o. within 45 minutes of ingestion. Plasma anti-FXa level about four hours after ingestion > 4.00 IU/ml. At 13.5 hours after ingestion was 1.51 IU/ml. No adverse effects reported. No bleeding complication.
Rivaroxaban ³	6 year old girl	Severe Protein S deficiency with repetitive skin necrosis during warfarin treatment.	Stepwise increase up to 40 mg daily	No adverse effects reported at 1 year follow-up. No bleeding episodes.
Rivaroxaban ⁴	4 year old boy	Thrombotic storm	Daily dose unknown. Longterm treatment.	No bleeding or other adverse effects after 1 year of continues administration.
Edoxaban ⁵	4 year old boy	Protein C deficiency	2 mg/kg/dose, four times a day	Two years follow-up did not result in adverse events.
Apixaban ⁶	3 year old girl, 2 & 6 year old boys	Intracardiac thrombosis	2.5 mg twice a day	No bleeding events, complete resolution of the thrombi (n=2), substantial reduction in clot size (n=1) (follow up 6 days - 4 weeks)

Hermann S et al.: Pharmacokinetics of a microdosed cocktail of 3 direct oral anticoagulants in children with congenital heart defects: study protocol for a single centre clinical trial, 2022.

<https://mc.manuscriptcentral.com/bmjpo>

bmjpo-2022-001666 on 31 January 2023. Downloaded from <http://bmjpaedsopen.bmj.com/> on April 27, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

1. Van Bruwaene L, Huisman A, Urbanus RT, et al. Heparin-resistant Thrombosis Due to Homozygous Antithrombin Deficiency Treated With Rivaroxaban: A Case Report. *J Pediatr Hematol Oncol* 2016;38(8):658-60. doi: 10.1097/MPH.0000000000000608
2. Carr BM, Roy DJ, Bangh SA, et al. Anti-factor Xa Monitoring and Activated Charcoal for a Pediatric Patient With Rivaroxaban Overdose. *Clin Pract Cases Emerg Med* 2018;2(3):247-50. doi: 10.5811/cpcem.2018.5.38373
3. Martinelli I, Bucciarelli P, Artoni A, et al. Anticoagulant treatment with rivaroxaban in severe protein S deficiency. *Pediatrics* 2013;132(5):e1435-9. doi: 10.1542/peds.2013-1156
4. Ma JY, Zhang X, Li XF, et al. Thrombotic storm in a 4-year-old boy with a thrombus in the right atrium. *Int J Immunopathol Pharmacol* 2018;32:2058738418778121. doi: 10.1177/2058738418778121
5. Watanabe K, Arakawa Y, Yanagi M, et al. Management of severe congenital protein C deficiency with a direct oral anticoagulant, edoxaban: A case report. *Pediatric blood & cancer* 2019;66(6):e27686. doi: 10.1002/pbc.27686
6. Esch JJ, Hellinger A, Friedman KG, et al. Apixaban for treatment of intracardiac thrombosis in children with congenital heart disease. *Interactive cardiovascular and thoracic surgery* 2020;30(6):950-51. doi: 10.1093/icvts/ivaa041 [published Online First: 2020/03/30]

Hermann S et al.: Pharmacokinetics of a microdosed cocktail of 3 direct oral anticoagulants in children with congenital heart defects: study protocol for a single centre clinical trial, 2022.

<https://mc.manuscriptcentral.com/bmjpo>

BMJ Paediatrics Open

Pharmacokinetics of a microdosed cocktail of 3 direct oral anticoagulants in children with congenital heart defects: study protocol for a single centre clinical trial (DOAC-Child)

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2022-001662.R1
Article Type:	Protocol
Date Submitted by the Author:	15-Nov-2022
Complete List of Authors:	Hermann, Simon; UniversitätsKlinikum Heidelberg, Department of Clinical Pharmacology and Pharmacoepidemiology Mikus, Gerd; UniversitätsKlinikum Heidelberg, Department of Clinical Pharmacology and Pharmacoepidemiology Chobanyan-Jürgens, Kristine; UniversitätsKlinikum Heidelberg, Department of Clinical Pharmacology and Pharmacoepidemiology; UniversitätsKlinikum Heidelberg, Pediatric Clinical-Pharmacological Trial Centre Gorenflo, Matthias; UniversitätsKlinikum Heidelberg, Department of Paediatric and Congenital Cardiology Ziesenitz, Victoria; UniversitätsKlinikum Heidelberg, Department of Paediatric and Congenital Cardiology
Keywords:	Cardiology, Pharmacology

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 1 **Pharmacokinetics of a microdosed cocktail of 3 direct oral anticoagulants in children with**
4 **congenital heart defects: study protocol for a single centre clinical trial (DOAC-Child)**

5
6
7 3 **Simon A. Hermann¹, Gerd Mikus¹, Kristine Chobanyan-Jürgens^{1,3}, Matthias Gorenflo²,**
8 **Victoria C. Ziesenitz²**
9
10

11 5 ¹ Department of Clinical Pharmacology and Pharmacoepidemiology

12 6 Heidelberg University Hospital

13 7 Im Neuenheimer Feld 410

14 8 69120 Heidelberg, Germany

15 9 ² Centre for Child and Adolescent Medicine – Department of Paediatric and Congenital
16 10 Cardiology

17 11 Heidelberg University Hospital

18 12 Im Neuenheimer Feld 430

19 13 69120 Heidelberg, Germany

20 14 ³ Pediatric Clinical-Pharmacological Trial Centre (paedKliPS) - Centre for Pediatric and
21 15 Adolescent Medicine

22 16 Heidelberg University Hospital

23 17 Im Neuenheimer Feld 430

24 18 69120 Heidelberg, Germany

25 19

26 20 **Corresponding author:**

27 21 Victoria C. Ziesenitz

28 22 Centre for Child and Adolescent Medicine – Department of Paediatric and Congenital

29 23 Cardiology

30 24 Heidelberg University Hospital

31 25 Im Neuenheimer Feld 430

32 26 69120 Heidelberg, Germany

33 27 Email: ziesenitz.md@gmail.com

34 28 Telephone: +49 6221/56 4605

35 29 **ORCID:**

36 30 SAH: <https://orcid.org/0000-0002-5561-8022>

37 31 GM: <https://orcid.org/0000-0003-1783-133X>

38 32 KCJ: <https://orcid.org/0000-0002-9118-9464>

1
2
3 1 MG: <https://orcid.org/0000-0002-3326-5959>

4
5 2 VCZ: <https://orcid.org/0000-0003-2836-4212>

6
7
8 **3 Authors' contributions:**

9
10 4 SAH: writing of trial protocol and manuscript, sub-investigator, conduct of the trial.

11
12 5 GM: conception of the trial, writing of trial protocol, biostatistician.

13
14 6 KCJ: conception of the trial, writing of trial protocol, deputy investigator

15
16
17 7 MG: conception of the trial, writing of trial protocol, principal investigator, conduct of
18
19 8 the trial

20
21 9 VCZ: conception of the trial, writing of trial protocol, deputy investigator, conduct of
22
23 10 the trial

24
25
26
27 **11 Word count:**

28
29 12 Manuscript: 2576 words (2500)

30
31 13 Abstract: 286 words (300)

32
33 **14 Trial registration numbers:**

34
35 15 EudraCT 2019-001759-38

36
37 16 DRKS00021455

38
39
40 **17 Declaration of interests:**

41
42 18 This is an investigator initiated clinical trial sponsored by the Heidelberg University Hospital,
43
44 19 there are no financial interests of any person involved.

45
46
47 **20 Funding:**

48
49 21 There was no external funding received for the conduct of this study.

50
51
52 22

1 **Abstract**

2 **Introduction:** Direct oral anticoagulants (DOACs) are direct inhibitors of coagulation factor
3 Xa and are frequently used in adults for different indications such as deep vein thrombosis or
4 non-valvular atrial fibrillation. Paediatric patients might benefit as well from DOACs because
5 the simplicity and convenience of their use is likely to decrease physical and psychological
6 stress related to invasive procedures associated with phenprocoumon and heparin therapy. Thus
7 it is expected that the future use of DOACs will ultimately improve compliance and overall
8 safety of anticoagulant therapies in paediatric populations. To assure safe and effective use the
9 clinical pharmacology and pharmacokinetics (PK) of these drugs need to be evaluated in
10 children.

11 **Methods and analysis:** This study is a single centre, open-label, clinical trial in a paediatric
12 population with non-cyanotic congenital heart defects. After having obtained informed consent
13 from the parents, each participant will receive a single oral administration of a drinkable
14 solution of a microdose cocktail of 3 FXa inhibitors consisting of apixaban (12.5 µg),
15 rivaroxaban (12.5 µg), edoxaban (50 µg), plus a microdose of the two probe drugs midazolam
16 (10 µg) and yohimbine (25 µg). Serial blood samples (n=up to 20) will be collected at specified
17 time points before and up to 25 h after cocktail administration. The primary PK endpoint will
18 be the area under the plasma concentration time curve ($AUC_{0-\infty}$) of apixaban, rivaroxaban and
19 edoxaban. Secondary PK outcomes will be C_{max} , t_{max} , $t_{1/2}$, Cl/F , and V_{ss}/F . Safety and
20 tolerability of the microdose cocktail will be evaluated as well by collection of adverse events.

21 **Ethics:** This study has been approved by the responsible Ethics Committee of the Medical
22 Faculty of Heidelberg University.

23 **Dissemination:** Study results will be presented at international scientific meetings and
24 published in peer-reviewed journals.

25

1 **What is known about the subject?**

- 2 • Current anticoagulation regimes in children with congenital heart defects consist of
3 phenprocoumon, (low molecular weight) heparin, or antiplatelet agents. Disadvantages
4 of these regimes comprise invasive monitoring (phenprocoumon) or invasive
5 administration techniques (heparin).
- 6 • Direct oral anticoagulants (DOAC) are a relatively new class of anticoagulants which
7 have been approved and are widely used in adults.
- 8 • There are no data available regarding the pharmacokinetics of DOACs in pediatric heart
9 patients.
- 10 • The expression of drug metabolising enzymes involved in the eliminations of DOACs
11 varies during human development and growth, but might be influenced by genetic
12 polymorphisms of drug metabolising enzymes as well.

13 **What this study hopes to add:**

- 14 • Evaluation of the pharmacokinetics of three DOACs: rivaroxaban, edoxaban, apixaban
15 simultaneously in children with congenital heart defects aged 6 months to 6 years using
16 a microdose-cocktail approach.
- 17 • Evaluation of CYP3A and CYP2D6 metaboliser status using the microdosed probe
18 drugs midazolam and yohimbine in pediatric heart patients.

19 **How this study might affect research, practice and/ or policy.**

- 20 • The pharmacokinetics of rivaroxaban, edoxaban and apixaban will be evaluated
21 regarding their interindividual variability and their potential for drug-drug interactions.
- 22 • The DOAC with the most favorable profile will be selected and a subsequent study
23 using therapeutic doses will be conducted.

- 1
2
3 1 • The overall goal of this study is to pave the way for less painful pediatric
4
5 2
6 anticoagulation.
7
8 3
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Confidential: For Review Only

1 Introduction

2 Congenital heart defects (CHD) are the most common major congenital anomalies. Congenital
3 heart defects are defined as a structural abnormality of the heart and/or great vessels that is
4 present at birth. Reported birth prevalence of CHD varies between 8-12 per 1000 live births^{1 2}.
5 The prevalence of complex CHD is reported to be 0.8 to 2.2 per 1000 live births depending on
6 the demographics of the study population, the inclusion criteria, and the study era. Severe CHD
7 account for most of the morbidity and mortality attributable to CHD³.

8 A recent German analysis which focused on patients with CHD born between 1996 and 2015
9 showed that the number of patients with severe CHD had increased significantly since
10 2008/2009. About 9.4% of patients in this cohort had complex CHD classified as univentricular
11 heart⁴. Certain patients with severe congenital heart defects require temporary or lifelong
12 anticoagulation. This applies especially to patients after biological (temporary anticoagulation)
13 or mechanical (lifelong anticoagulation) heart valve replacement, or patients after Glenn or
14 Fontan palliation, when the blood flows passively through the pulmonary circulation at low
15 velocity.

16 The currently used anticoagulants in children are either oral phenprocoumon or warfarin,
17 heparin continuous infusion, and subcutaneously injected low molecular weight heparins, the
18 latter often limited to short-term therapy.

19 Since 2008, direct oral anticoagulants (DOAC) including the drugs dabigatran, rivaroxaban,
20 apixaban and edoxaban have been approved for adults in Europe and the US, and efficacy,
21 safety and pharmacokinetic data have been obtained in adults.

22 An oral microdose DOAC cocktail (μ -FXaI) containing apixaban (25 μ g), edoxaban (50 μ g)
23 and rivaroxaban (25 μ g) has been successfully used in adults to study drug-drug interactions^{5 6}.

24 Comparing the pharmacokinetics (PK) of these 3 μ -FXaI, obtained after simultaneous
25 administration⁸ with the PK characteristics after therapeutic DOAC doses from literature
26 showed DOAC clearances always in the same range (dose-proportional pharmacokinetics)⁷⁻⁹.

1
2
3 1 In addition, comparable to already published drug interaction data of therapeutic doses a drug-
4
5 2 drug interaction study using ketoconazole in 18 healthy adults (> 18 years) and μ -FXaI revealed
6
7 3 quantitative comparable effects on the clearances of μ -FXaI⁵.

8
9
10 4 These drugs so far have not yet been adequately studied in children and are currently not
11
12 5 approved for the use in children with congenital heart defects. For children and adolescents,
13
14 6 there are ongoing studies on rivaroxaban and apixaban, but most of them are not yet completed
15
16 7 or published^{10 11} (in addition, see supplement 1).

17
18
19 8 Only few studies focusing on DOACs in children have been carried out so far, or are still
20
21 9 ongoing^{10 12}. Currently, there are only limited data published for edoxaban or apixaban in
22
23 10 children¹³. The few results from studies of rivaroxaban PK report a favorable safety profile and
24
25 11 PK comparable to those already known for adults¹².

26
27
28 12 There are body-weight adjusted treatment recommendations available for rivaroxaban in
29
30 13 children with venous thromboembolism. Children with a body weight 10 kg or more should be
31
32 14 treated with a daily dose of 9 mg or higher, depending on the actual body weight¹⁴. Assessment
33
34 15 of 92 children aged < 6 months – 17 years with weight-adjusted rivaroxaban after previous
35
36 16 therapeutic treatment with common medication such as low-molecular weight heparin because
37
38 17 of venous thromboembolism was performed. No major bleeding was observed during the
39
40 18 clinical trial in 92 children aged < 6 months to 17 years.

41
42
43
44
45 19 Therefore, it is important to generate pharmacokinetic data of DOAC in children of young age
46
47 20 with congenital heart defects without an increased risk of bleeding, which would be harmful to
48
49 21 this vulnerable group. The simultaneous pharmacokinetic assessment of three molecules within
50
51 22 the same study is an elegant, modern, ethically-adequate design, allowing to limit discomfort
52
53 23 to both participants and their families.

54
55
56
57
58 24 In order to obtain data of CYP3A and CYP2D6 activity in young children, microdosed co-
59
60 25 administration of the CYP3A substrate midazolam (MDZ; 10 μ g) and the CYP2D6 substrate

1 yohimbine (YOH; 25 µg) as probe drugs along with the µ-FXaI will be carried out. These both
2 drugs were proven to function as microdosed probe drugs for phenotyping these enzymes by
3 showing dose linearity^{15 16}. Pharmacogenomics of further enzymes, transporters, etc. could
4 influence the PK of the respective drugs as well, however including more substrates into this
5 first microdose approach in children seems not feasible yet. . Thus, the microdose cocktail to
6 be used in the study contains a total of 5 different drugs which will be administered
7 simultaneously by oral route.

8

9

1 **Methods and analysis**

2 **Study Design**

3 This is an open-label, single-centre, single dose clinical trial in a paediatric population with
4 non-cyanotic congenital heart defects at the Department of Paediatric and Congenital
5 Cardiology of the Heidelberg University Hospital in cooperation with the paediatric Clinical
6 Pharmacological Trial Centre (paedKliPS). This protocol was designed following the SPIRIT
7 guidelines¹⁷.

8 **Study population**

9 Infants and children aged 6 months up to 6 years with a body weight >7 kg who are admitted
10 to the paediatric cardiology wards for the surgical correction on a non-cyanotic congenital heart
11 defect will be eligible for study inclusion. Children who are treated with anticoagulants, who
12 have a coagulopathy or lesions or conditions which are associated with a significant risk for
13 major bleeding are excluded, as well as children who have kidney or liver insufficiency, or are
14 treated with drugs known to be relevant inducers or inhibitors of drug metabolizing enzymes.
15 Detailed inclusion and exclusion criteria are listed in Table 1.

16 For the purpose of surgery all patients are under routine continuous cardiorespiratory
17 monitoring (Intellivue, Philips Healthcare, Eindhoven, The Netherlands) and have central
18 vascular access. Depending on the age and the clinical condition, most patients have a feeding
19 tube as well.

20 **Primary objective**

21 Assessment of the pharmacokinetics of rivaroxaban, apixaban and edoxaban, when co-
22 administered as a microdose cocktail (apixaban 12.5 µg, rivaroxaban 12.5 µg, edoxaban 50 µg)
23 in children with congenital heart defects, aged 6 months to 6 years.

1 **Secondary objectives**

- 2 • To compare the pharmacokinetics of the FXaI in children with those reported in healthy
- 3 adults and patients from literature.
- 4 • To characterise the CYP3A activity by means of a midazolam microdose in children.
- 5 • To characterise the CYP2D6 activity by means of a yohimbine microdose in children.
- 6 • To evaluate tolerability (and safety regarding laboratory parameters) of this microdose
- 7 cocktail in children.

8 **Study Outcome**

9 Primary outcome is the area under the concentration-time curve ($AUC_{0-\infty}$) of the three DOACs
10 apixaban, edoxaban, and rivaroxaban. Secondary outcomes include standard PK parameters
11 (C_{max} , t_{max} , $t_{1/2}$, Cl/F , and V_{ss}/F) of each FXaI and yohimbine, as well as the metabolic clearance
12 of midazolam by means of AUC_{2-4h} ¹⁸.

13 **Recruitment**

14 Recruitment takes place at the Department of Paediatric and Congenital Cardiology. Prior to
15 the surgical intervention parents of potential participants will be addressed by a study physician
16 regarding the study which serves as short information about the clinical trial. After the surgery
17 detailed information will be given and discussed with both parents. After full explanation of the
18 purpose, the procedures involved, the expected duration, the potential risks and benefits and
19 any discomfort of the clinical trial both parents will be asked whether they agree to participate
20 and, in that case, to sign the informed consent form before any study procedures are carried out.

21 **Screening**

1 The screening visit is defined as accurate check of all diagnostic findings which were made in
2 course of the pre-operative assessment to evaluate eligibility. This is done after the surgery by
3 a trial team physician in order to check inclusion and exclusion criteria.

4 ***Interventions***

5 The intervention begins as early as on postoperative day 3 (about 72 hours after surgery) with
6 the oral administration of the study drugs. They are dissolved in 110 ml drinking water to ensure
7 comfortable oral application. If the patient has a feeding tube, this will be used for
8 administration and will afterwards be flushed with 5mL drinking water. All patients have as a
9 clinical routine measure prior to cardiac surgery a central venous line. Vital parameters and
10 other clinical or laboratory which are necessary to ensure patients safety are extracted from the
11 daily documentation during clinical routine.

12 ***Sample collection***

13 PK blood samplings will be collected via a central venous line and time points are dependent
14 on bodyweight (Figure 1). The total amount of blood drawn will be 25 mL over 25 hours for
15 children of at least 10 kg. This includes 17 samples to evaluate PK parameters (S-Monovette®
16 1.2 mL lithium heparin collection tubes, Sarstedt, Nümbrecht, Germany) and 3 safety checks
17 in which the coagulation parameters will be observed (S-Monovette® 1.4 mL citrate collection
18 tubes, Sarstedt, Nümbrecht, Germany). Blood samples for the DOAC PK-analysis (Li-Hep)
19 will be obtained before and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, and 25 h after
20 intake of the oral solution. This is equivalent to a loss of blood volume of 3.28 % of a child
21 weighing 10 kg. For children weighing 7 to 9.9 kg a reduced sampling scheme (12 PK samples
22 and 3 coagulation samples, specific timepoints are before and 0.25, 0.5, 1, 1.25, 2, 2.5, 3, 4, 8,
23 12, and 24 h after intake of the oral solution.) will be performed to limit the blood loss (18.6 mL
24 in 24 hours equivalent to 3.54 % for a child weighing 7 kg)¹⁹. All PK samples will be quantified

1 by ultra-performance liquid chromatography – tandem mass spectrometry methods in the
2 Clinical Analytical Laboratory of the Department of Clinical Pharmacology and
3 Pharmacoepidemiology at the University Hospital Heidelberg.

4 Midazolam will be measured in 5 samples (before and 2, 2.5, 3, and 4 h after administration)
5 using an established limited sampling strategy¹⁸ and yohimbine²⁰ in the samples taken up to 12
6 hours after administration.

7 Three coagulation checks (quick, INR, aPTT) are obtained before, 2 and 2425 h after drug
8 administration.

9 ***End of trial***

10 After the last blood sample the end of trial visit includes reviewing the last clinical examination
11 and laboratory assessment, which both are performed at least once during 24 hours by clinical
12 routine.

13 ***Concomitant medication***

14 Any necessary medication (judged by a responsible physician) for the best clinical care and/or
15 emergency treatment is permitted. Concomitant medication will be documented (date, time,
16 dose, route of administration) by a member of the trial team. For safety reasons simultaneous
17 administration of anticoagulants, thrombolytics, platelet inhibitors such as GPIIb/IIIa-inhibitors
18 and P2Y₁₂ inhibitors, and thienopyridine (clopidogrel) are prohibited for the duration of the
19 trial.

20 ***Sample size calculation***

21 Since no PK data in young children are available for the microdosed FXaI cocktail, no formal
22 sample size calculation could be performed. It is planned to enroll up to 20 children with
23 congenital heart defects. This number of patients is consistent with sample sizes of similar

1 exploratory PK studies, which is expected to provide sufficient information on PK, safety
2 regarding laboratory parameters, and tolerability of the μ -FXaI cocktail and the suitability of
3 this methodology in future clinical paediatric drug development. In addition, it is expected that
4 robust single-dose PK data of 3 FXaI in a young paediatric population will be generated to
5 provide first guidance for dose adjustment in clinical use.

6 **Data management**

7 Clinical routine data are also documented for this clinical trial. Vital signs (i.e. blood pressure,
8 heart rate) are documented at screening, prior to the drug administration, at any specific PK
9 timepoint, and at end of trial. Concomitant medication and adverse events are also recorded.
10 Printed source data sheets are used for the primary data collection and documentation. All
11 source data information are timely transferred to the clinical trial management database
12 (Promasys, OmniComm Systems, Fort Lauderdale, USA).

13 **Data analysis and missing data**

14 Standard PK parameters (C_{\max} , t_{\max} , $AUC_{0-\infty}$, $t_{1/2}$, Cl/F , and V_{ss}/F) of each FXaI and yohimbine
15 will be calculated by non-compartmental analyses (Monolix 2021R2, Lixoft SAS, Antony,
16 France) and its results will be presented by descriptive statistics (GraphPad Prism 8.0.0 for
17 Windows, GraphPad Software, San Diego, California USA). CYP3A activity will be quantified
18 using the estimated metabolic clearance of midazolam by means of AUC_{2-4h} .

19 Individual missing or inconsistent data will be subject to a simple edit query process. Eventually
20 missing data will not be imputed.

21 **Patient and Public Involvement**

22 Patients and/ or the public were not involved in any stages of this clinical trial: study design/
23 conduction/ analysis.

1 **Ethics and dissemination**

2 **Ethics approval**

3 The study protocol (Version 4.0), patient information and informed consent form were
4 approved by the ethics committee of the Medical Faculty of Heidelberg University (AFmo-
5 606/2019) and the German competent authority (BfArM).

6 To enable the participation for children younger than 2 years and with a weight lower than
7 10 kg a protocol amendment was submitted and approved (Protocol Version 5.1). For these
8 patients, a reduced sampling scheme was introduced to keep the relative loss of blood volume
9 below 5 % in 24 hours¹⁹.

10 **Study monitoring**

11 A trained clinical trial monitor is assigned from the Department of Clinical Pharmacology and
12 Pharmacoepidemiology at the University Hospital Heidelberg to perform the monitoring of this
13 clinical trial.

14 **Safety considerations**

15 All medications will be administered as a subtherapeutic microdose. Although it is unlikely that
16 the achieved concentrations of the administered trial medications confer any pharmacological
17 effect or adverse drug reaction, a maximum degree of safety is essential in this vulnerable
18 population. Clinical monitoring as per standard of care after cardiac surgery will be used.

19 **Benefit and Risk assessment**

20 There is no direct benefit to the patients or their parents. Because of the clinical setting in which
21 the study will be carried out, no additional invasive procedures have to be performed. All
22 participants are admitted as inpatient to the paediatric cardiac wards, where continuous
23 cardiorespiratory monitoring and central vascular access, etc. are already provided.

1
2
3 1 In order to reduce additional burden of study procedures to the patient in the postoperative
4
5 2 phase, after having signed informed consent, the patients' medical history, findings during the
6
7 3 clinical examination and other parameters routinely assessed and documented during the
8
9 4 treatment for these patients will also be completely recorded for this clinical trial. Due to the
10
11 5 sensitive drug assay, the amount of blood taken for the PK analyses is minimised.
12
13

14
15 6 All study drugs will be given as single microdoses only which does not elicit any
16
17 7 pharmacological effects or adverse events⁵. The combination of microdoses of apixaban,
18
19 8 rivaroxaban, edoxaban has been used in adults and at FXaI peak concentrations, International
20
21 9 normalised ratio (INR) increased just by 3.9% and activated partial thromboplastin time (aPTT)
22
23 10 by 3.1% which was clinically not relevant⁵. No bleeding complications occurred. Clinically
24
25 11 relevant non-major bleeding (menorrhagia and gingival bleeding) has been observed in four
26
27 12 children with venous thromboembolism taking therapeutic rivaroxaban within the Einstein-Jr
28
29 13 phase III study²¹.
30
31

32
33 14 Due to very sensitive analytical assay for apixaban and rivaroxaban, the dose of apixaban and
34
35 15 rivaroxaban is halved to 12.5 µg each compared to the adult study. MDZ and yohimbine were
36
37 16 used frequently in adults and no relevant AEs were observed at all.
38
39

40
41 17 Thus, the risk for adverse events (AE) or toxicity is minimal. We do not expect any bleeding
42
43 18 complications by µ-FXaI. If a case of bleeding complications the effects of rivaroxaban and
44
45 19 apixaban can be reversed by Andexanet alpha. It also inhibits the function of all heparins²². We
46
47 20 have summarised the case reports where children were exposed to rivaroxaban or edoxaban²³,
48
49 21 intentionally or unintentionally in the Table 2.
50

51
52 22 In summary, potential risks of participation in this clinical trial are small and predictable. The
53
54 23 trial drugs are administered at sub-therapeutic microdoses on one occasion, so that no Type A
55
56 24 adverse drug reactions are expected. The participant's suitability will be carefully evaluated,
57
58 25 and their health will be closely monitored during the trial.
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Publications and Data access**

2 The results of this investigation will be published in an international scientific peer-reviewed
3 journal. It is not planned to make the data publicly available.

4

Confidential: For Review Only

1
2
3 **Figure 1:** Study design assessing the pharmacokinetics of rivaroxaban, apixaban, edoxaban as
4 well as the CYP3A and CYP2D6 enzyme activity in children with congenital heart defects.
5
6
7 Upper timeline: Sampling schedule for children weighing 10 kg and more, lower timeline:
8
9 sampling schedule for children weighing 7-9.9 kg. CR = Blood sampling within clinical routine.
10
11
12 EOT = End of trial
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Table 1: Detailed inclusion and exclusion criteria of DOAC-Child**

<i>Inclusion criteria</i>	<i>Exclusion criteria</i>
<ul style="list-style-type: none"> • Infants and children aged 6 months up to 6 years (inclusive) • Body weight ≥ 7 kg • Admitted as inpatient to the paediatric cardiac wards after congenital cardiac surgery • Cardiac defects: non-cyanotic congenital heart defects such as e.g. atrial septal defect, ventricular septal defect • Availability of a central vascular access • Otherwise healthy children as determined by medical assessment consisting of a medical history, physical examination, an ECG, and a laboratory evaluation, all performed within the clinical routine, that all must show no clinically relevant abnormalities • Minor deviations of laboratory values from the normal range may be acceptable in the pre-operative assessment, if judged by the investigator to be of no clinical relevance for this trial. <p>Criteria include, but are not limited to</p> <ul style="list-style-type: none"> • $ALT \leq ULN \times 1.1$ • $AST \leq ULN \times 1.2$ 	<ul style="list-style-type: none"> • Intake of a substance known to induce or inhibit drug metabolizing enzymes or drug transporters within a period of less than 10 times the respective elimination half-life or two weeks, whatever is longer • Simultaneous treatment with anticoagulants (i.e. phenprocoumon, warfarin, heparin - prior intake of heparin is allowed if more than 24 h prior to the start of study) • Active, clinically relevant bleeding • Any hepatic disease which could lead to coagulopathy or clinically relevant risk of bleeding • Lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities • Uncontrolled severe hypertension/hypotension • Severe respiratory insufficiency

<ul style="list-style-type: none"> • Bilirubin \leq ULN x 1.2 (this does not apply to patients with Gilbert's syndrome) • Creatinine \leq ULN + 0.1 mg/dl (=ULN + 8.8 μmol/L) • Haemoglobin > 10 g/dl (pre- and postoperatively) • Both parents (or legal representatives) have to be able to communicate well with the investigator, to understand and comply with the requirements of the trial • Voluntarily signed informed consent after full explanation of the objectives, meaning and consequences of the trial to both parents (or legal representatives) of the participant. The informed consent will be obtained after the surgery but before any specific study procedures will be carried out 	<ul style="list-style-type: none"> • Tachycardic arrhythmias • Renal/Liver insufficiency • Glaucoma • Gastrointestinal ulceration • Clinically relevant mental disorder • Any physical disorder that could interfere with the participant's safety during the clinical trial or with the trial objectives • Body weight lower than 7 kg • Allergies (except for mild forms of hay fever) or history of hypersensitivity reactions/ intolerance to the study drugs • Any acute or chronic illness or clinically relevant finding during the clinical course known or expected to modify absorption, distribution, metabolism, or excretion of the drug under investigation • Any participation in an interventional clinical trial within 30 days before inclusion. • Specific exclusion criteria for Midazolam: Administration of midazolam less than 48 h prior to the start of study
--	---

1

2

1 **Table 2: Case reports about children who were exposed to direct oral anticoagulants**

DOAC	Patient	Indication	Dose	Result
Rivaroxaban ²⁴	12 year old girl	DVT	20 mg once daily for 5 days	Rivaroxaban trough level after 2 days 109 ng/mL and after 5 days 100 ng/mL. No bleeding.
Rivaroxaban ²⁵	35 month old boy	Accidental intake	200 mg (16 mg/kg)	Activated charcoal (2 g/kg) p.o. within 45 minutes of ingestion. Plasma anti-FXa level about four hours after ingestion > 4.00 IU/mL. At 13.5 hours after ingestion was 1.51 IU/mL. No adverse effects reported. No bleeding complication.
Rivaroxaban ²⁶	6 year old girl	Severe Protein S deficiency with repetitive skin necrosis during warfarin treatment.	Stepwise increase up to 40 mg daily	No adverse effects reported at 1 year follow-up. No bleeding episodes.
Rivaroxaban ²⁷	4 year old boy	Thrombotic storm	Daily dose unknown. Longterm treatment.	No bleeding or other adverse effects after 1 year of continued administration.
Edoxaban ²³	4 year old boy	Protein C deficiency	2 mg/kg/dose, four times a day	Two years follow-up did not result in adverse events.
Apixaban ¹³	3 year old girl, 2 & 6 year old boys	Intracardiac thrombosis	2.5 mg twice a day	No bleeding events, complete resolution of the thrombi (n=2), substantial reduction in clot size (n=1) (follow up 6 days – 4 weeks)

2

3


1 References

1. Liu Y, Chen S, Zuhlke L, et al. Global birth prevalence of congenital heart defects 1970-2017: updated systematic review and meta-analysis of 260 studies. *Int J Epidemiol* 2019 doi: 10.1093/ije/dyz009
2. van der Linde D, Konings EE, Slager MA, et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. *Journal of the American College of Cardiology* 2011;58(21):2241-7. doi: 10.1016/j.jacc.2011.08.025 [published Online First: 2011/11/15]
3. Egbe A, Uppu S, Lee S, et al. Changing prevalence of severe congenital heart disease: a population-based study. *Pediatric cardiology* 2014;35(7):1232-8. doi: 10.1007/s00246-014-0921-7 [published Online First: 2014/05/16]
4. Pfitzer C, Helm PC, Ferentzi H, et al. Changing prevalence of severe congenital heart disease: Results from the National Register for Congenital Heart Defects in Germany. *Congenital heart disease* 2017;12(6):787-93. doi: 10.1111/chd.12515 [published Online First: 2017/07/19]
5. Mikus G, Foerster KI, Schaumaeker M, et al. Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs. *Clinical pharmacokinetics* 2019 doi: 10.1007/s40262-019-00749-1
6. Rohr BS, Foerster KI, Blank A, et al. Perpetrator Characteristics of Azole Antifungal Drugs on Three Oral Factor Xa Inhibitors Administered as a Microdosed Cocktail. *Clinical pharmacokinetics* 2022;61(1):97-109. doi: 10.1007/s40262-021-01051-9 [published Online First: 2021/07/18]
7. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. *Drug Metab Dispos* 2009;37(1):74-81. doi: 10.1124/dmd.108.023143 [published Online First: 2008/10/04]

- 1
2
3 1 8. Vakkalagadda B, Frost C, Byon W, et al. Effect of Rifampin on the Pharmacokinetics of
4
5 2 Apixaban, an Oral Direct Inhibitor of Factor Xa. *American journal of cardiovascular*
6
7 3 *drugs : drugs, devices, and other interventions* 2016;16(2):119-27. doi:
8
9 4 10.1007/s40256-015-0157-9 [published Online First: 2016/01/11]
10
11
12 5 9. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of
13
14 6 single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. *Clinical*
15
16 7 *pharmacology and therapeutics* 2005;78(4):412-21. doi: 10.1016/j.clpt.2005.06.011
17
18 8 [published Online First: 2005/10/04]
19
20
21 9 10. von Vajna E, Alam R, So TY. Current Clinical Trials on the Use of Direct Oral
22
23 10 Anticoagulants in the Pediatric Population. *Cardiol Ther* 2016;5(1):19-41. doi:
24
25 11 10.1007/s40119-015-0054-y [published Online First: 2016/01/08]
26
27
28 12 11. Payne RM, Burns KM, Glatz AC, et al. A multi-national trial of a direct oral anticoagulant
29
30 13 in children with cardiac disease: Design and rationale of the Safety of ApiXaban On
31
32 14 Pediatric Heart disease On the preventioN of Embolism (SAXOPHONE) study.
33
34 15 *American heart journal* 2019;217:52-63. doi: 10.1016/j.ahj.2019.08.002 [published
35
36 16 Online First: 2019/09/08]
37
38
39 17 12. Male C, Thom K, O'Brien SH. Direct oral anticoagulants: What will be their role in
40
41 18 children? *Thromb Res* 2019;173:178-85. doi: 10.1016/j.thromres.2018.06.021
42
43 19 [published Online First: 2018/07/19]
44
45
46 20 13. Esch JJ, Hellinger A, Friedman KG, et al. Apixaban for treatment of intracardiac
47
48 21 thrombosis in children with congenital heart disease. *Interactive cardiovascular and*
49
50 22 *thoracic surgery* 2020;30(6):950-51. doi: 10.1093/icvts/ivaa041 [published Online
51
52 23 First: 2020/03/30]
53
54
55 24 14. Lensing AWA, Male C, Young G, et al. Rivaroxaban versus standard anticoagulation for
56
57 25 acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III
58
59
60

- 1
2
3 1 study. *Thromb J* 2018;16:34. doi: 10.1186/s12959-018-0188-y [published Online
4
5 2 First: 2019/01/02]
6
7 3 15. Halama B, Hohmann N, Burhenne J, et al. A nanogram dose of the CYP3A probe
8
9 substrate midazolam to evaluate drug interactions. *Clinical pharmacology and*
10 4
11 *therapeutics* 2013;93(6):564-71. doi: 10.1038/clpt.2013.27
12 5
13 16. Vay M, Meyer MJ, Blank A, et al. Oral Yohimbine as a New Probe Drug to Predict
14 6
15 CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial. *Clin Pharmacokinet*
16 7
17 2020;59(7):927-39. doi: 10.1007/s40262-020-00862-6
18 8
19 17. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard
20 9
21 protocol items for clinical trials. *Ann Intern Med* 2013;158(3):200-7. doi:
22 10
23 10.7326/0003-4819-158-3-201302050-00583 [published Online First: 2013/01/09]
24 11
25 18. Katzenmaier S, Markert C, Riedel KD, et al. Determining the time course of CYP3A
26 12
27 inhibition by potent reversible and irreversible CYP3A inhibitors using A limited
28 13
29 sampling strategy. *Clinical pharmacology and therapeutics* 2011;90(5):666-73. doi:
30 14
31 10.1038/clpt.2011.164 [published Online First: 2011/09/23]
32 15
33 19. Howie SR. Blood sample volumes in child health research: review of safe limits. *Bull*
34 16
35 *World Health Organ* 2011;89(1):46-53. doi: 10.2471/BLT.10.080010 [published
36 17
37 Online First: 2011/02/25]
38 18
39 20. Vay M, Sauter M, Mikus G, et al. Quantification of microdosed oral yohimbine and its
40 19
41 major metabolite in human plasma in the picogram range. *Bioanalysis*
42 20
43 2019;11(16):1459-67. doi: 10.4155/bio-2019-0129 [published Online First:
44 21
45 2019/08/15]
46 22
47 21. Monagle P, Lensing AWA, Thelen K, et al. Bodyweight-adjusted rivaroxaban for children
48 23
49 with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-
50 24
51 arm, phase 2 studies. *Lancet Haematol* 2019;6(10):e500-e09. doi: 10.1016/S2352-
52 25
53 3026(19)30161-9 [published Online First: 2019/08/20]
54 26
55
56
57
58
59
60

- 1
2
3 1 22. Baumann Kreuziger L, Karkouti K, Tweddell J, et al. Antithrombotic therapy
4 management of adult and pediatric cardiac surgery patients. *Journal of thrombosis and*
5
6 2 *haemostasis : JTH* 2018;16(11):2133-46. doi: 10.1111/jth.14276
7
8 3
9
10 4 23. Watanabe K, Arakawa Y, Yanagi M, et al. Management of severe congenital protein C
11
12 5 deficiency with a direct oral anticoagulant, edoxaban: A case report. *Pediatric blood*
13
14 6 *& cancer* 2019;66(6):e27686. doi: 10.1002/pbc.27686
15
16
17 7 24. Van Bruwaene L, Huisman A, Urbanus RT, et al. Heparin-resistant Thrombosis Due to
18
19 8 Homozygous Antithrombin Deficiency Treated With Rivaroxaban: A Case Report. *J*
20
21 9 *Pediatr Hematol Oncol* 2016;38(8):658-60. doi: 10.1097/MPH.0000000000000608
22
23
24 10 25. Carr BM, Roy DJ, Bangh SA, et al. Anti-factor Xa Monitoring and Activated Charcoal for
25
26 11 a Pediatric Patient With Rivaroxaban Overdose. *Clin Pract Cases Emerg Med*
27
28 12 2018;2(3):247-50. doi: 10.5811/cpcem.2018.5.38373
29
30
31 13 26. Martinelli I, Bucciarelli P, Artoni A, et al. Anticoagulant treatment with rivaroxaban in
32
33 14 severe protein S deficiency. *Pediatrics* 2013;132(5):e1435-9. doi: 10.1542/peds.2013-
34
35 15 1156
36
37 16 27. Ma JY, Zhang X, Li XF, et al. Thrombotic storm in a 4-year-old boy with a thrombus in
38
39 17 the right atrium. *Int J Immunopathol Pharmacol* 2018;32:2058738418778121. doi:
40
41 18 10.1177/2058738418778121
42
43
44
45 19
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Study design assessing the pharmacokinetics of rivaroxaban, apixaban, edoxaban as well as the CYP3A and CYP2D6 enzyme activity in children with congenital heart defects. Upper timeline: Sampling schedule for children weighing 10 kg and more, lower timeline: sampling schedule for children weighing 7-9.9 kg. CR = Blood sampling within clinical routine. EOT = End of trial.

254x190mm (96 x 96 DPI)

Hermann S et al.: Pharmacokinetics of a microdosed cocktail of 3 direct oral anticoagulants in children with congenital heart defects: study protocol for a single centre clinical trial, 2022.

Supplementary Material

Rivaroxaban

NCT number	Anticipated end date	Current status	Results
01684423	January 2016	completed	https://clinicaltrials.gov/ct2/show/results/NCT01684423?term=Rivaroxaban%2C+Children&draw=2&rank=2
02497716	April 2016	completed	
02564718	October 2016	completed	https://clinicaltrials.gov/ct2/show/results/NCT02564718?term=Rivaroxaban%2C+Children&draw=2&rank=5
02309411	March 2017	completed	https://clinicaltrials.gov/ct2/show/results/NCT02309411?term=Rivaroxaban%2C+Children&draw=2&rank=1
02234843	November 2018	completed	https://clinicaltrials.gov/ct2/show/results/NCT02234843?term=Rivaroxaban%2C+Children&draw=2&rank=3

Apixaban

NCT number	Anticipated end date	Current status	Results
01707394	August 2016	completed	
02369653	May 2019	completed	https://clinicaltrials.gov/ct2/show/results/NCT02369653?term=Apixaban%2C+Children&draw=2&rank=1
02464969	October 2020	recruiting	

Edoxaban

NCT number	Anticipated end date	Current status	Results
02303431	December 2016	completed	

Hermann S et al.: Pharmacokinetics of a microdosed cocktail of 3 direct oral anticoagulants in children with congenital heart defects: study protocol for a single centre clinical trial, 2022.

Dabigatran

NCT number	Anticipated end date	Current status	Results
01083732	November 2015	completed	https://clinicaltrials.gov/ct2/show/results/NCT01083732?term=Dabigatran%2C+Children&draw=2&rank=2
01773174	December 2015	withdrawn	
02223260	April 2016	completed	https://clinicaltrials.gov/ct2/show/results/NCT02223260?term=Dabigatran%2C+Children&draw=2&rank=1
01895777	March 2018	completed	https://clinicaltrials.gov/ct2/show/results/NCT01895777?term=Dabigatran%2C+Children&draw=2&rank=6
02197416	June 2018	completed	https://clinicaltrials.gov/ct2/show/results/NCT02197416?term=Dabigatran%2C+Children&draw=2&rank=3